Microdosing for Depression and Anxiety: What the Clinical Evidence Actually Shows

Microdosing is one of the most widely discussed and least well-supported practices in the psychedelic field. The gap between what people report and what controlled research has been able to demonstrate is unusually large, and anyone weighing microdosing for depression and anxiety deserves to see that evidence clearly rather than filtered through enthusiasm. What follows is an honest account of what the trials have found, why the results look the way they do, and what the practical implications are for someone genuinely struggling with mood or anxiety.

What Is Microdosing, Exactly?

Microdosing means taking a psychedelic at a dose low enough that it produces no noticeable alteration in perception or consciousness. You are not meant to feel high. You are meant to go to work, run a meeting, and function normally, with the theory being that something subtle is shifting underneath.

Typical amounts fall well below the doses used in clinical psychedelic therapy. For psilocybin, common microdosing regimens use roughly 0.1 to 0.3 grams of dried mushroom, taken one to three times per week over a period of weeks to months, which is on the order of one tenth of a therapeutic dose. For LSD, controlled research has generally used somewhere between 5 and 20 micrograms, compared with the 100 to 200 micrograms that produce a full experience.

Two schedules dominate the practice. The Fadiman protocol involves dosing once every three days. The Stamets protocol uses several consecutive days followed by a break, often with additional supplements. Both originated in citizen science rather than clinical research, and neither has been validated against the other in a controlled setting. A closer look at the schedules themselves is available in our overview of the Fadiman and Stamets microdosing protocols and what the clinical data says.

Why Do So Many People Say Microdosing Works?

Survey data on microdosing is genuinely striking. Large observational studies routinely find that most people who microdose report improved mood, reduced anxiety, better focus, and increased creativity. These are not fringe reports. They come from thousands of people, and they are sincere.

The problem is that observational data cannot separate the effect of a drug from the effect of expecting a drug to work. People who choose to microdose have usually read about it, believe in it, and are actively watching themselves for improvement. That combination produces a powerful expectancy effect, which is exactly the thing controlled trials exist to filter out.

What Do Placebo-Controlled Trials Show About Microdosing for Depression and Anxiety?

This is where the microdosing depression anxiety evidence becomes uncomfortable for the practice, and where it is worth reading carefully.

The largest placebo-controlled study of microdosing to date used an unusual design. Researchers at Imperial College London recruited people who were already microdosing and taught them to blind themselves, preparing identical capsules of real microdoses and placebos so that they did not know which they were taking on any given day. The study was completed by 191 participants, making it the largest placebo-controlled psychedelic trial conducted up to that point.

The results were unambiguous in one direction. Participants who believed they had taken a microdose reported improvements in mood, creativity, and anxiety, but so did participants who believed they had taken a microdose and had actually swallowed a placebo. The expectation of a microdose produced the same psychological benefits as the microdose itself. Both groups improved. Neither group improved more than the other.

A separate double-blind study in Argentina looked specifically at psilocybin. Researchers recruited 34 people who were beginning to microdose with dried Psilocybe cubensis and tested the acute and short-term effects of a half-gram dose on mood, creativity, perception, cognition, and brain activity under placebo-controlled conditions. Microdosed psilocybin did not improve mood, well-being, creativity, or cognition, and the authors suggested positivity bias helped explain the more favorable results reported in uncontrolled settings.

Reviews of the controlled literature have reached similar conclusions on the specific question of anxiety and mood. Across the controlled microdosing studies, no difference was found in depression and anxiety scale scores following psilocybin microdosing, and no change in state or trait anxiety.

What we can say with confidence is this. When you remove the expectation, most of the benefit disappears.

Is There Any Clinical Signal at All?

There is, and it deserves fair treatment rather than dismissal.

The most serious clinical work on microdosing for depression is happening at the University of Auckland. Their open-label Phase 2A trial gave 19 participants with major depressive disorder sixteen doses of LSD over eight weeks, starting at 8 micrograms and ranging from 6 to 20 micrograms twice weekly at home, with the first dose given in clinic. The regimen was well tolerated with no serious adverse effects, and the researchers observed a pronounced and long-lasting reduction in depression severity across the intervention period. Depression scores on the Montgomery-Åsberg scale fell by roughly 59.5 percent by the end of treatment, with the improvement sustained at six months.

Those numbers look impressive. They should also be read with the study’s own caution attached. This was an open-label trial, which means everyone involved knew they were receiving LSD. There was no placebo group. The researchers themselves describe the findings as preliminary antidepressant signals and are proceeding to a Phase 2B randomized controlled trial specifically to test whether LSD outperforms placebo. Given that every well-controlled microdosing study so far has found no advantage over placebo, that trial is the one that matters.

The research is early, and the honest position is that we do not yet know. What we do know is that the burden of proof has not been met.

How Does This Compare to Full-Dose Psychedelic Therapy?

The contrast is stark, and it is the single most important thing for a seeker to understand.

Full-dose, professionally supported psilocybin therapy for depression has produced substantial and durable symptom reductions in multiple randomized controlled trials, with effects in some participants persisting for months after a single session. Ketamine has an established antidepressant effect measured in hours rather than weeks. MDMA-assisted therapy has generated the strongest results of any psychedelic modality for PTSD.

Microdosing has produced none of that. It is not a milder version of the same thing. The mechanism that appears to drive therapeutic change in full-dose work, a period of heightened neural flexibility paired with psychological support, is largely absent at sub-perceptual doses. Taking a tenth of a dose does not deliver a tenth of the benefit. On the current evidence, it appears to deliver something much closer to nothing, at least on average.

If you want a picture of what the higher-dose research actually supports, our comparison of psilocybin and ketamine therapy covers the evidence base for both.

Is Microdosing Safe?

Safety is a separate question from efficacy, and the answer is more reassuring, with real caveats.

Low doses of psilocybin and LSD are generally well tolerated in controlled research, with minimal physiological effects in healthy volunteers. The Auckland trial included cardiac monitoring with echocardiography and ECG precisely because repeated exposure to serotonergic compounds raises theoretical concerns about heart valve tissue over long periods. That is not a hypothetical worry invented by skeptics. It is a known issue with other drugs that act on the same receptor system, and it is why open-ended, years-long microdosing without medical oversight is not something we would encourage.

The other risks are practical. Unregulated material means unknown potency, and a “microdose” cut from an unusually strong specimen may not be sub-perceptual at all. People taking SSRIs, lithium, MAOIs, or other psychiatric medications face interaction questions that a microdosing forum cannot answer. Anyone with a personal or family history of psychosis or bipolar disorder should treat any psychedelic, including a small one, as contraindicated until a clinician says otherwise. A full account is in our guide to psychedelic therapy contraindications and who should pause first.

What Should You Do If You Are Struggling With Depression or Anxiety?

Here is the honest advice, which is not the exciting one.

If you are dealing with clinical depression or an anxiety disorder, microdosing is not a treatment. It has been tested and has not passed. Spending six months on a protocol that performs no better than placebo means six months not spent on something with an actual evidence base, and for someone in genuine distress that delay carries a cost.

This matters because the psychedelic field does have serious options. Ketamine is legally accessible and clinically supported in most of the United States. Regulated psilocybin services exist in Oregon and Colorado. Professionally guided work with a trained practitioner, in a prepared setting, with structured integration afterward, is where the research has actually delivered results.

None of this means people who microdose are foolish, or that the placebo response they experience is not real to them. Feeling better is feeling better. But there is a difference between a practice that makes you feel like you are doing something and a treatment that changes the underlying condition, and the microdosing depression anxiety evidence currently points firmly to the former.

If you are trying to figure out whether a psychedelic approach makes sense for your situation, that question is worth working through with someone who knows the evidence and has no incentive to oversell it.